Resumen
Objetivo: Identificar las manifestaciones clínicas gastrointestinales prevalentes en pacientes con COVID-19 en un hospital de Goiás, en el año 2021. Métodos: Se trata de un estudio observacional, realizado con recolección de datos de 153 historias clínicas, realizado en el un hospital en Goiás. Se investigó la presencia de síntomas gastrointestinales al ingreso y durante la evolución, además del sexo, edad, comorbilidades previas, marcadores hepáticos y canaliculares, desenlace clínico. Los datos obtenidos fueron analizados por estadística descriptiva con la ayuda del software BI. El estudio fue aprobado por el Comité de Ética en Investigación. Resultados: La mayor parte de la muestra tenía entre 40 y 59 años (41,8 %), del sexo masculino (50,3 %) y presentaba alguna comorbilidad previa, siendo la más frecuente la hipertensión arterial sistémica (41,1 %). Se encontró una alta prevalencia de síntomas gastrointestinales, presentes en la mayoría de los pacientes evaluados (18,3%). Los síntomas más frecuentes al ingreso fueron inapetencia (66%), náuseas (22,6%) y diarrea (18,9%), y los síntomas más frecuentes durante la evolución fueron estreñimiento (63,1%), inapetencia (38,1%) y diarrea (17,1%). Conclusión: Se concluye que la mayoría de los pacientes con COVID-19 presentaron síntomas gastrointestinales en algún momento.
Referencias
BRITO APSO, et al. Manifestações gastrointestinais em pacientes infectados pelo SARS-CoV-2: Revisão sistemática da literatura. Brazilian Journal of Health Review, 2020; 3(5):14570-14583.
CAI Q, et al. COVID-19: Abnormal liver function tests. Journal of hepatology, 2020; 73(3): 566-574.
CUICCHI D, et al. Fecal-oral transmission of SARS-CoV-2: review of laboratory-confirmed virus in gastrointestinal system. International journal of colorectal disease, 2020; 36: 437-444.
DHAR D, MOHANTY A. Gut microbiota and COVID-19 - possible link and implications. Virus research, 2020, 285: 1-6.
DING S, LIANG TJ. Is SARS-CoV-2 also an enteric pathogen with potential for fecal-oral transmission? A COVID-19 clinical and virological review. Elsevier Public Health Emergency Collection: Gastroenterology, 2020; 159 (1): 53-61.
GOYAL H, et al. Clinical insights into the gastrointestinal manifestations of COVID-19. Nature Public Health Emergency Collection, 2020; 65(1): 1932-1939.
HUNG YP, et al. Gut Dysbiosis during COVID-19 and Potential Effect of Probiotics. Microrganisms, 2021; 9(8): 1605-1616.
KAAFARANI HMA, et al. Gastrointestinal Complications in Critically Ill Patients With COVID-19. Annals of surgery, 2020; 272(2): 61-62.
KHAN MU, et al. Digestive system involvement and clinical outcomes among COVID-19 patients: A retrospective cohort study from Qatar. World J Gastroenterol, 2021; 27(46): 7995-8009.
KOPEL J, et al. Clinical Insights into the Gastrointestinal Manifestations of COVID-19. Nature Public Health Emergency Collection, 2020; 23: 1-8.
KRISHNAN A, et al. Abnormal liver chemistries as a predictor of COVID-19 severity and clinical outcomes in hospitalized patients. World J Gastroenterol, 2022; 28(5): 570-587.
LEI F, et al. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. Hepatology, 2020; 72(2): 389-398.
MARQUES RDC, et al. A pandemia de COVID-19: Interseções e desafio para a história da saúde e do tempo presente. Coleção História do Tempo Presente, 2020; 3: 225-249.
MONTAZERI M, et al. Clinical characteristics of COVID-19 patients with gastrointestinal symptoms. Arch Iran Med, 2021; 24(2): 131-136.
MORAIS LRD, et al. COVID-19 e o trato gastrointestinal: fisiopatologia e evolução clínica dos pacientes. Brazilian Journal of Health Review, 2021, 4(2): 4556-4569, 2021.
OGASSAWARA, MY, et al. Sintomas gastrointestinais em pacientes com COVID-19: relação com a gravidade e complicações da doença, Revista Eletrônica Acervo Saúde, 2021; 27: e7817.
PENNINGER JM, et al. The Role of Angiotensin Converting Enzyme 2 in Modulating Gut Microbiota, Intestinal Inflammation, and Coronavirus Infection. Gastroenterology, 2020; 160(1): 39-46.
RAMACHANDRAN P, et al. Gastrointestinal Symptoms and Outcomes in Hospitalized Coronavirus Disease 2019 Patients. Dig Dis, 2020; 38(5): 373-379.
RIOS DL, et al. Probióticos: como uma microbiota intestinal saudável ajuda a combater infecções respiratórias virais agudas, similares à covid-19. Revista Eletrônica Acervo Saúde, 2020; 46: e3537.
TABARY M, et al. Pathologic features of COVID-19: A concise review. Pathology-Research and Practice, 2020, 216(9): 1-5.
SUN Y, et al. Gastrointestinal and hepatic injury associated with COVID-19: clinical characteristics and potential mechanisms. Signal Transduction and Targeted Therapy, 2020; 256 (5): 1-8.
XAVIER-SANTOS D, et al. Evidences and perspectives of the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention and treatment of COVID-19: A bibliometric analysis and systematic review. Trends in Food Science & Technology, 2022; 120: 174-192.
YE Q, et al. The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19. Am J Physiol Gastrointest Liver Physiol, 2020, 319(2): G245-G252.
ZHANG F, et al. Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications. Nature Reviews Gastroenterology & Hepatology, 2023, 20(5): 323-337
ZHONG P, et al. COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. Signal Transduction and Targeted Therapy, 2020, 5(1): 1-8.
